Tigermed Thrives in 2026 with Strong Interim Results and Strategic Collaborations

Hangzhou Tigermed Consulting Co., Ltd. announced its 2026 interim results, showcasing impressive growth across various segments. During the Reporting Period, the company’s revenue increased by 14.1% year-over-year to RMB 3,707.6 million. Tigermed’s Gross Profit also saw a positive trend, reaching RMB 1,020.5 million, an increase of 4.4% YoY. Moreover, the Adjusted Net Profit Attributable to the Owners of the Company surged by 31.8% YoY to RMB 277.7 million. The Clinical Trial Solutions segment proved to be a significant revenue driver during the Reporting Period, with revenue hitting RMB 1,773.4 million, up 20.7% YoY. Similarly, the Clinical-related and Lab Services segment…